DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Gluz O, Nitz U, Liedtke C. et al.
No survival benefit of chemotherapy escalation in patients with pCR and high-immune triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial.
San Antonio Breast Cancer Symposium 2018; Abstr. GS5-06
We do not assume any responsibility for the contents of the web pages of other providers.